Drugmakers Biogen Inc. and Eisai Co. said Thursday that they are ending two late-stage trials for an experimental Alzheimer’s therapy, the latest failure in efforts to find a drug that can stymie the memory-robbing disease. The announcement, which said an independent committee found the trials for the experimental drug aducanumab were unlikely to succeed, sent shares of both companies plunging more than 25%. Biogen lost about $18 billion in market value.

Source: Wall Street Journal March 21, 2019 12:19 UTC